Sonoma Pharmaceuticals, Inc. (SNOA, Financial) saw a significant stock price increase of 5.00%, reaching $2.94 per share. The trading volume was 38,078 shares with a turnover rate of 2.84% and a price fluctuation of 6.96%. The company's latest financial report recorded a revenue of $3.39 million and a net loss of $1.14 million, resulting in an earnings per share of -$1.34. The gross profit stood at $1.31 million, and the price-to-earnings ratio was -0.47. Among the analysts covering the stock, 100% have given a buy recommendation.
Within the pharmaceutical sector, Sonoma Pharmaceuticals' stock movement contrasts with an overall industry decline of 0.70%. Other notable stocks exhibiting significant price increases include Alvotech C/Wts and Alpha Teknova, Inc., while companies like Akanda Corp. and Canopy Growth Corporation showed high trading activity. Cyclo Therapeutics Inc C/Wts, Journey Medical Corporation, and Cbdmd, Inc. experienced substantial fluctuations in their stock prices.
Sonoma Pharmaceuticals, Inc. is a U.S.-based specialist in medical dermatology, focusing on developing and commercializing treatments for chronic skin conditions like acne, atopic dermatitis, and scars. Their product lineup includes solutions like Celacyn and Ceramax, among others, targeting various skin treatments. The company generates revenue from sales across North America, Latin America, Europe, Asia, and other regions.
